



7th AROME – MONTENEGRO COURSE

Bridge between Science and Clinics in Oncology

6th AROME Montenegro Consensus Conference

Prioritizing Strategies for Access to Cancer
Care and Innovations in Emerging Countries

UNDER THE AUSPICES OF



Sharing Progress
in Cancer Care



Hotel Mediteran • Bečići, Budva, Montenegro
October, 1–4, 2025



7th AROME – MONTENEGRO COURSE

Bridge between Science and Clinics in Oncology

6th AROME Montenegro Consensus Conference

Prioritizing Strategies for Access to Cancer Care
and Innovations in Emerging Countries

1st to 4th October 2025 • Hotel Mediteran, Bečići – Budva, Montenegro

PRESIDENCY:

Vladimir TODOROVIC

(Meeting President)

Institute for Oncology, Clinical Center of Montenegro,
University of Montenegro, Podgorica, Montenegro

Joseph GLIGOROV

(AROME former President)

Institut Universitaire de Cancérologie
APHP-Sorbonne Université, Paris, France

Matti AAPRO

(President – Sharing Progress in cancer Care, SPCC)
Clinique du Génohier, Génohier, Switzerland

SCIENTIFIC COMMITTEE:

M Aapro (Switzerland), Y Belkacemi (France), J Gligorov (France),
A. Eniu (Switzerland), V. Todorović (Montenegro), P. Tsoutsou (Greece)

MEETING ORGANIZATION AND REGISTRATION CONTACT:



ASTAKOS
Travel & Events

Novi ASTAKOS Travel & Events

e-mail: congress@astakos.com • www.astakos.com

WEDNESDAY 1st OCTOBER 2025

HALL A

Opening session

12:30–13:30	Registration and welcome coffee	
13:30–13:45	AROME WELCOME	Joseph Gligorov (France) Vladimir Todorović (Montenegro)

HALL A

Session 1: Innovations in diagnostics

CHAIRS: Dragana Bogdanović Stojanović (Serbia) & Nina Radošević (France)

14:00–14:30	Evolutions in molecular imaging	Khalidoun Kerrou (France)
14:30–15:00	AI & Imaging & screening	Isabelle Thomassin (France)
15:00–15:30	Liquid biopsy	Radmila Janković (Serbia)
15:30–16:00	Coffee break	

HALL A

Session 2: Innovations in locoregional treatments

CHAIRS: Ivan Marković (Serbia) & Nebojša Crnogorac (Montenegro)

16:00–16:30	Innovation in surgery	Nada Santrač (Serbia)
16:30–17:00	Interventional radiology: are all techniques crucial?	Sanja Stojanović (Serbia)
17:00–17:30	Radiotherapy	Yazid Belkacemi (France)
17:30–18:30	INDUSTRY SPONSORED SESSION – GLOSARIJ CD – MSD KEYTRUDA and the journey from extended survival to potential cure in certain tumor types Clinical evidence and ESMO MCBS scores across indications - from advanced to early stages MODERATOR: Lazar Popović PANELISTS: Marijana Milović-Kovačević, Timur Cerić	

THURSDAY 2nd OCTOBER 2025

HALL A

Session 3: Gastro Intestinal cancers treatments innovations

CHAIRS: Nenad Mijalković (Serbia) & Milan Risteski (North Macedonia)

09:00–09:30	News in pathology and molecular diagnosis	Filip Vukmirović (Montenegro)
09:30–10:00	News in adjuvant colorectal cancers	Biljana Kukić (Serbia)
10:00–10:30	News in metastatic colorectal cancers	Nenad Mitreski (North Macedonia)
10:30–11:00	News in non-colorectal GI cancers	Romain Cohen (France)
11:00–11:30	Coffee break	

HALL A

Session 4: Lung cancers treatments innovations

CHAIRS: Vladimir Kovčin (Serbia) & Adda Bounedjar (Algeria)

11:30–11:50	Screening and prevention	Jelena Đekić Malbaša (Serbia)
11:50–12:10	Treatment options in inoperable localized lung cancers	Felipe De Sousa (Switzerland)
12:10–12:30	Innovations in immunotherapy for lung cancers	Timur Cerić (Bosnia & Herzegovina)
12:30–12:50	Innovations in targeted treatments for lung cancers	Sanja Pleština (Croatia)
13:00–14:30	Lunch break	

HALL A

Session 5: Urogenital cancers treatments innovations

CHAIRS: Zoran Džamić (Serbia) & Nevenka Lukovac Janjić (Montenegro)

14:45–15:05	Optimal treatment sequences in localized prostate cancer	Dušanka Tešanović (Serbia)
-------------	--	----------------------------

15:05–15:35	Innovations in prostate and renal cancers	Lazar Popović (Serbia)
15:35–15:55	Innovations in bladder cancers	Milan Risteski (North Macedonia)
15:55–16:25	Coffee break	

HALL A

Session 6: Supportive care

CHAIRS: Sedat Turkan (Turkey) & Hassan Errihani (Morocco)

16:35–17:05	Innovations in pain management	Tomi Kovačević (Serbia)
17:05–17:35	Cardiotoxicity in Systemic Oncology treatment	Marko Musić (Montenegro)

FRIDAY 3rd OCTOBER 2025

HALL A

Session 7: Cancer and fertility

CHAIRS: Joseph Gligorov (France) & Zorica Tomašević (Serbia)

08:30–08:50	Fertility preservation	Natalija Dedić Plavetić (Croatia)
08:50–09:10	Cancer during pregnancy	Snezana Šušnjar (Serbia)
09:10–09:30	Pregnancy after cancer	Snežana Crnogorac (Montenegro)
09:30–09:45	Coffee break	

HALL A

Session 8: Breast cancers treatments innovations

CHAIRS: Vladimir Todorović (Montenegro) & Marijana Milović Kovačević (Serbia)

09:45–10:05	Innovations in HER2 positive disease	Assia Konsoulova (Bulgaria)
10:05–10:25	Innovations in TNBC	Hamouda Boussen (Tunisia)
10:25–10:45	Innovations in HR+/HER2 neg	Ivana Božović Spasojević (Serbia)
10:45–10:50	Coffee break	

10:50–11:50	INDUSTRY SPONSORED SESSION NOVARTIS (COFFEE SERVED INSIDE) Reducing Risk and Improving Treatment Outcomes: Ribociclib in Early HR+/HER2- Breast Cancer MODERATOR: Vladimir Todorović LECTURERS: Nikola Milašević, Marijana Milović, Joseph Gligorov
11:55–12:55	INDUSTRY SPONSORED SESSION ASTRA ZENECA (COFFEE SERVED INSIDE) Shaping Momentum and Destiny of Breast Cancer in the Region CHAIR: Lazar Popović, Serbia LECTURERS AND PANELISTS: Natalija Dedić Plavetić, Croatia, Ivana Božović Spasojević, Serbia, Assia Konsoulova, Bulgaria, Nikola Milašević, Montenegro
13:00–14:00	INDUSTRY SPONSORED SESSION ROCHE (COFFEE SERVED INSIDE) Navigating the Complexity of Breast Cancer: From the HER2 Paradigm to PIK3CA Breakthroughs CHAIR: Vladimir Todorović Roche legacy of anti-HER2 treatment: Bridging Clinical Trials and Real-World Practice in Montenegro – Nada Cicmil Sarić Unmet Need in 1L PIK3CAmut HR+/HER2- BC: How can we improve patient outcomes in HR+ mBC? – Ana Cvetanović
14:00–15:00	Lunch break

HALL A

Session 9: Gynecologic cancers treatments innovations

CHAIRS: Suzana Vasović (Serbia) & Gordana Bašović (Montenegro)

15:00–15:30	Innovations in gynecological surgery	Iztok Takač (Slovenia)
15:30–16:00	Innovations in gynecological radiotherapy	Goran Marošević (Croatia)
16:00–16:30	Innovations in targeted treatments for ovarian cancers	Marijana Milović Kovačević (Serbia)

16:30–17:00	Innovations in targeted treatments for cervical and endometrial cancers	Violeta Klisarovska (North Macedonia)
17:00–17:15	Coffee break	

HALL A

Session 10: Head & Neck, Melanoma & CNS cancers treatments innovations

CHAIRS: Nikola Milašević (Montenegro) & Dušanka Tešanović (Serbia)

17:15–17:45	Innovation in Head & Neck	Esat Mahmut Ozsahin (Switzerland)
17:45–18:05	Innovation in Melanoma	Borislava Nikolin (Serbia)
18:05–18:25	Innovation in CNS and bone cancers	Igor Stojkovski (North Macedonia)
18:30–19:00	INDUSTRY SPONSORED SESSION MEDISON PHARMA The View of Uveal Melanoma – The Perspective of Patient Management Uveal Melanoma – Disease Characteristics – Borislava Nikolin Metastatic Uveal Melanoma – Treatment Guidelines and Patient Management – Ana Cvetanović	

SATURDAY 4th OCTOBER 2025

HALL A

AROME Montenegro Consensus conference
Prioritizing Strategies for Access to Cancer Care and Innovations in Emerging Countries (Endorsed by Oncology Section Serbian Medical Society)

Joseph Gligorov (France), Vladimir Todorovic (Montenegro),
 Alexandru Eniu (Switzerland) & Ivan Marković (Serbia)

10:00–12:00	Expert discussion and voting session
12:00–12:15	Closing remarks

THURSDAY 2nd OCTOBER 2025

HALL B

INDUSTRY SPONSORED SESSIONS

16:05–16:35	INDUSTRY SPONSORED SESSION MERCK CHAIR: Zoran Džamić The importance of Bavencio in treatment of urothelial cancer – Zoran Džamić Efficacy and safety of Bavencio in the treatment of LA/mUC – Lazar Popović Bavencio – experiences from real clinical practice in the treatment of LA/mUC – Nevenka Lukovac Janjić
16:35–17:05	Industry sponsored session MEDICO PHARMACIA Clinical studies with Cabazitaxel – Lazar Popović
17:05–17:50	INDUSTRY SPONSORED SESSION ASTRA ZENECA EVOLVING ROLE OF CALQUENCE IN PRACTICE LECTURES: Vesko Vujičić, Montenegro, Ivana Miketić, Montenegro, Nikola Bakić, Montenegro
17:50–18:20	INDUSTRY SPONSORED SESSION AMICUS Renal Cell Carcinoma: Current Overview – Zoran Džamić Opdivo + Yervoy in RCC: Durable Outcomes and Clinical Impact – Lazar Popović 2L management of RCC: The role of Opdivo – Nevenka Lukovac Janjić

FRIDAY 3rd OCTOBER 2025

HALL B

INDUSTRY SPONSORED SESSIONS

10:30–11:00	INDUSTRY SPONSORED SESSION PFIZER Integrating Lorlatinib Into First-Line ALK+ NSCLC Treatment Focus on Lorlatinib; Transforming Patient Outcomes in ALK+ NSCLC – Nikola Milašević Optimizing Long-term Treatment with Lorlatinib: Balancing Efficacy and Safety – Ana Delić Vukićević
--------------------	--

We are leading a revolution in oncology to redefine cancer care

AstraZeneca 

Lynparza®
olaparib 

ENHERTU®
trastuzumab deruxtekten 

IMFINZI®
durvalumab 

TAGRISSO®
osimertinib 


CALQUENCE®
acalabrutinib 

AstraZeneca 

Predstavništvo AstraZeneca UK Limited Beograd
Mikutina Milankovića 11, Beograd
Tel: 011 3336 900
SAMO ZA STRUČNU JAVNOST
RS-7492, septembar 2025.

Prije propisivanja lijekova kompanije AZ, molimo pročitajte posljednje odobrene Sažetke karakteristike lijekova: Enherthu, Sažetak karakteristika lijeka, Septembar 2025, Lynparza, Sažetak karakteristika lijeka, Jul 2023, Imfinzi, Sažetak karakteristika lijeka, April 2025, Tagrisso, Sažetak karakteristika lijeka, April 2025, Calquence, Sažetak karakteristika lijeka, Septembar 2024.





In eBC

**NO NEWS IS
GOOD NEWS**

 **KISQALI®**
ribociclib

Novartis Pharma Services AG
d.o.o. stranog društva Podgorica
ul. Svetlane Kane Radevic br. 3,
Podgorica, Crna Gora

Only for healthcare professionals
ME_0925_FA-11510720

 **NOVARTIS**



Novartis advances medicine through research aimed at improving the quality and length of life. As a leading global pharmaceutical company, we use innovative science and digital technologies to create transformative treatments in areas of special medical importance. Our purpose is to reimagine medicine to improve and extend people's lives. In our search for new medicines, we rank among the world's leading companies that invest in research and development. Our vision is to become the most valued and trusted pharmaceutical company in the world.

Novartis' medicines affect the lives of nearly 800 million people worldwide, and we are constantly looking for innovative ways to expand access to our newest therapies. There are currently more than 30 new molecules in the research phase. About 78,000 people in approximately 120 countries are employed by Novartis.

Our strategy is to deliver high-value medicines that alleviate society's greatest disease through leadership in the field of technology applied in research and development, as well as new drug approaches.

To support this strategy, we have clearly defined focus areas and priorities for creating value for our company, our shareholders and society. Our focus is on five key therapeutic areas: cardiovascular disease, immunology, neuroscience, solid tumors and hematology.

Novartis Pharma Services AG
dionosno društvo Podgorica
ul. Svetlane Kane Radević br. 3,
Podgorica, Crna Gora
Only for healthcare professionals
ME_0925_FA-11510888

Using the power of leading-edge science to save and improve lives around the world

For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for some of the world's most challenging diseases.

At MSD, we rise to the challenge in pursuit of better health outcomes.



Nosilac dozvole za stavljanje lijeka u promet: "Glosarij" d.o.o.,
Vojislavljevića 76, Podgorica, Crna Gora
Tel.: +382 20 642 495; Fax.: +382 20 642 540

Veeva code: ME-NON-00027

Izrađeno Crnoj Gori, septembar 2025.

Sva prava pridržana.

Copyright ©2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved.







Roche u ONKOLOGIJI



Samo za stručnu javnost

Hoffmann - La Roche LTD, Representative Office Podgorica, Cetinjska 11, Sprat IV Biznis kula, Capital plaza, 81000 Podgorica, Crna Gora, Telefon: +382 20 241 823 | M-ME-00001189

*Pratimo nauku
stvaramo inovacije
mijenjamo živote*



Posjetite sajt Roche Crna Gora

www.rohecg.me



NOTES

NOTES

NOTES

PLATINUM PLUS SPONSOR



PLATINUM SPONSORS



BRONZE SPONSOR



SPONSORS



MEDICOPHARMACIA

